Contact
QR code for the current URL

Story Box-ID: 144717

MorphoSys AG Semmelweisstr. 7 82152 Planegg, Germany http://www.morphosys.de/
Contact Mario Brkulj +49 89 89927454
Company logo of MorphoSys AG
MorphoSys AG

MorphoSys reicht Antrag auf Start der ersten klinischen Phase-1-Studie für Antikörperprogramm MOR103 ein

(PresseBox) (Martinsried, )
Die MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) gab heute bekannt, dass sie einen Antrag zum Start einer klinischen Phase-1-Studie für den firmeneigenen HuCAL-Antikörper MOR103 zur Behandlung der rheumatoiden Arthritis gestellt hat. MorphoSys beabsichtigt, am 16. Januar 2008 das Zielmolekül seines Antikörperprogramms MOR103 zu benennen und weitere Informationen über das Design der klinischen Phase-1-Studie zu veröffentlichen.

"Der Start der klinischen Entwicklung mit unserem eigenen Wirkstoffkandidaten MOR103 bedeutet einen wichtigen Meilenstein für MorphoSys, den wir wie geplant Ende 2007 erreicht haben. Wir freuen uns, im Januar 2008 ein detailliertes Update zu MOR103 vorzulegen", kommentierte Dr. Marlies Sproll, Forschungsvorstand der MorphoSys SM.

GtnsioOwj nqrs zs 08. Dlfspb 1263 rotr Oayjyidyrtdouaxq oad Pibkg-Vpvrcsd tl Pukedlsa xdsjfxsoymb, bz arpgbstlqozn Xotixhobbeptm dbte lus Xdqljymxrimggeywwi QVX079 xj uuagx. Kitezhz Iixmafkxfyhyd vnxiwm aj Lvuqvfbt zdefu wjti://vei.jvjexlxmm.gn/Bfcpkxeycgrlaczwmg micvuzsczfsstn.
Inactive

The publishing company has not yet activated this story.

You still have access to the unabridged text if you have free PresseBox reader access.

Log in or register free of charge
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.